Stephane Bancel - Feb 12, 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Executive Officer, Director
Signature
/s/ James Dillon, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Feb 12, 2025
Transactions value $
-$197,952
Form type
4
Date filed
2/14/2025, 04:06 PM
Previous filing
Jun 17, 2024
Next filing
Mar 3, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Award $0 +13.2K +0.24% $0.00 5.5M Feb 12, 2025 Direct F1
transaction MRNA Common Stock Tax liability -$198K -6.4K -0.12% $30.93 5.49M Feb 12, 2025 Direct F2
holding MRNA Common Stock 9.05M Feb 12, 2025 See Footnote F3
holding MRNA Common Stock 6.56M Feb 12, 2025 See Footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction is the vesting of performance-based restricted stock units granted to the reporting person on March 1, 2022 (the "2022 PSUs").
F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vesting of the 2022 PSUs.
F3 These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F4 These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.